Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain regarding tumor versus germline BRCA testing and the impact of heterozygous...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2021-12, Vol.163 (3), p.563-568
Hauptverfasser:	Hodgson, Darren R., Brown, Jessica S., Dearden, Simon P., Lai, Zhongwu, Elks, Cathy E., Milenkova, Tsveta, Dougherty, Brian A., Lanchbury, Jerry S., Perry, Michael, Timms, Kirsten M., Harrington, Elizabeth A., Barrett, J. Carl, Leary, Alexandra, Pujade-Lauraine, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use BRCA2 Protein - blood BRCA2 Protein - genetics Carcinoma, Endometrioid - blood Carcinoma, Endometrioid - genetics Clinical Trials, Phase III as Topic Fallopian Tube Neoplasms - blood Fallopian Tube Neoplasms - genetics Female Germ-Line Mutation Humans LOH and marker studies Loss of Heterozygosity Mutation detection methods Olaparib Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - genetics Peritoneal Neoplasms - blood Peritoneal Neoplasms - genetics Phthalazines - therapeutic use Piperazines - therapeutic use Polymorphism, Single Nucleotide Randomized Controlled Trials as Topic Ubiquitin-Protein Ligases - blood Ubiquitin-Protein Ligases - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!